ES2078356T3 - Derivados de la pirrolidina y de la piperidina. - Google Patents

Derivados de la pirrolidina y de la piperidina.

Info

Publication number
ES2078356T3
ES2078356T3 ES90917305T ES90917305T ES2078356T3 ES 2078356 T3 ES2078356 T3 ES 2078356T3 ES 90917305 T ES90917305 T ES 90917305T ES 90917305 T ES90917305 T ES 90917305T ES 2078356 T3 ES2078356 T3 ES 2078356T3
Authority
ES
Spain
Prior art keywords
alkyl
pct
formula
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917305T
Other languages
English (en)
Inventor
David Alker
Peter Edward Cross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2078356T3 publication Critical patent/ES2078356T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SEGUN LA INVENCION SE FACILITA UN COMPUESTO CON LA FORMULA (I) : R1-O(CH2)MA(CH2)NXR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN DONDE R1 ES UN GRUPO CON LA FORMULA (A O B) EN DONDE Z ES -(CH2)2-, -CH = CH-, -CH2-SPO CON LA FORMULA (C, D O HET) Y A ES UN GRUPO CON LA FORMULA (E, F O G)$0 EN EL QUE EL ATOMO DE N ESTA UNIDO AL GRUPO (CH2)N; M ES 1 O 2; N ES UN ENTERO DE DE 1 A 4; P ES 1, 2 O 3; R2 Y R3 SON CADA UNO INDEPENDIENTEMENTE HIDROGENO, C1-C4 ALQUILO, HIDROXI-(C1-C4 ALQUILO), HIDROXI, C1-C4 ALCOXI, HALO, TRIFLUOROMETILO, NITRO, CIANO, SULFAMOILO, -CO(C1-C4 ALQUILO), -OCO(C1-C4 ALQUILO), CARBOXI, -CO2(C1-C4 ALQUILO), -(CH2)QCONR4R5, -(CH2)QOCONR4R5, (CH2)QNR6R7 O -NHSO2NH2 EN DONDE R4 Y R5 SON CADA UNO INDEPENDIENTEMENTE H O C1-C4 ALQUILO, Q ES 0, 1 O 2 Y R6 Y R7 SON CADA UNO INDEPENDIENTEMENTE H O C1-C4 ALQUILO O R6 ES HIDROGENO Y R7 ES -SO2(C1-C4 ALQUILO), -CO(C1-C4 ALQUILO) O -CONH(C1-C4 ALQUILO); X ES UN ENLACE DIRECTO, O O S; Y E Y'' SON CADA UNO INDEPENDIENTEMENTE O O CH2; Y HET ES PIRIDILO, PIRACINILO O TIENILO. LOS COMPUESTOS SON UTILES COMO ANTAGONISTAS RECEPTORES MUSCARINICOS, PARTICULARMENTE EN EL TRATAMIENTO DEL SINDROME DE INTESTINO IRRITABLE.
ES90917305T 1990-01-06 1990-11-28 Derivados de la pirrolidina y de la piperidina. Expired - Lifetime ES2078356T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909000301A GB9000301D0 (en) 1990-01-06 1990-01-06 Piperidine & pyrrolidine derivatives

Publications (1)

Publication Number Publication Date
ES2078356T3 true ES2078356T3 (es) 1995-12-16

Family

ID=10668922

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917305T Expired - Lifetime ES2078356T3 (es) 1990-01-06 1990-11-28 Derivados de la pirrolidina y de la piperidina.

Country Status (14)

Country Link
US (1) US5344835A (es)
EP (1) EP0510003B1 (es)
JP (1) JPH0692365B2 (es)
AT (1) ATE128463T1 (es)
CA (1) CA2067758C (es)
DE (1) DE69022744T2 (es)
DK (1) DK0510003T3 (es)
ES (1) ES2078356T3 (es)
FI (1) FI922341A (es)
GB (1) GB9000301D0 (es)
GR (1) GR3017944T3 (es)
IE (1) IE69312B1 (es)
PT (1) PT96421B (es)
WO (1) WO1991010650A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP1061076B1 (en) * 1998-02-04 2004-12-08 Banyu Pharmaceutical Co., Ltd. N-acyl cyclic amine derivatives
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
JP4932994B2 (ja) * 1999-04-07 2012-05-16 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 抗癌性カルシウムチャンネル遮断薬
US8211916B2 (en) * 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
AU2001275537A1 (en) * 2000-06-20 2002-01-02 Wayne State University N-and o-substituted 4-(2-(diphenylmethoxy)-ethyl)-1-((phenyl)methyl)piperidine analogs and methods of treating cns disorders therewith
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
US8017791B2 (en) * 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US7368463B2 (en) * 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
JP2007528414A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
US7250414B2 (en) * 2004-03-11 2007-07-31 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
JP2007532672A (ja) 2004-04-16 2007-11-15 ウェイン ステート ユニバーシティ 三置換２−ベンズヒドリル−５−ベンジルアミノ−テトラヒドロ−ピラン−４−オール、及び６−ベンズヒドリル−４−ベンジルアミノ−テトラヒドロ−ピラン−３−オール類縁体、及び新規３，６−二置換ピラン誘導体
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE934890C (de) * 1951-10-07 1955-11-10 Chem Fab Promonta Ges Mit Besc Verfahren zur Herstellung von basischen Benzhydrylaethern
GB780027A (en) * 1955-01-20 1957-07-31 Schering Corp 3-piperidyl ethers and thioethers
US2974146A (en) * 1956-02-24 1961-03-07 Lakeside Lab Inc 3-piperidyl benzhydryl ethers
EP0228893A3 (en) * 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
US4810713A (en) * 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
GB8816365D0 (en) * 1988-07-08 1988-08-10 Pfizer Ltd Therapeutic agents
ES2118769T3 (es) * 1988-11-21 1998-10-01 Zeneca Ltd Fungicidas.

Also Published As

Publication number Publication date
GB9000301D0 (en) 1990-03-07
DK0510003T3 (da) 1996-01-29
JPH05501560A (ja) 1993-03-25
ATE128463T1 (de) 1995-10-15
CA2067758C (en) 1994-12-13
US5344835A (en) 1994-09-06
FI922341A0 (fi) 1992-05-22
DE69022744D1 (de) 1995-11-02
DE69022744T2 (de) 1996-03-07
JPH0692365B2 (ja) 1994-11-16
PT96421B (pt) 1997-05-28
EP0510003A1 (en) 1992-10-28
GR3017944T3 (en) 1996-02-29
WO1991010650A1 (en) 1991-07-25
FI922341A (fi) 1992-05-22
CA2067758A1 (en) 1991-07-07
IE69312B1 (en) 1996-09-04
PT96421A (pt) 1991-10-15
IE910020A1 (en) 1991-07-17
EP0510003B1 (en) 1995-09-27

Similar Documents

Publication Publication Date Title
ES2078356T3 (es) Derivados de la pirrolidina y de la piperidina.
DE69014901D1 (de) Muscarin-rezeptor-antagonisten.
CA2328780A1 (en) Dihydropyrimidines
DE69327541T2 (de) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
ATE402151T1 (de) 2-(arylphenyl)amino-imidazolin-derivate
EP0335979A4 (en) Thienopyrimidine derivatives
AU4258389A (en) Muscarinic receptor antagonists
DE69510510T2 (de) N-benzoylmethylsubstituierte paroxetinderivate
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
KR960007560A (ko) 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
EP0798304A4 (en) DRUGS AGAINST TRHOMBOCYTOPENIA
ES2057601T3 (es) Antagonistas de receptores muscarinicos.
NZ304988A (en) 1-omega-(3,4-dihydro-2-naphthalenyl)alkyl] cyclic amine derivatives and their use
DE69217148T2 (de) Isoxazole derivate als lichtschutzmittel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 510003

Country of ref document: ES